Atara Biotherap (ATRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 32,688 | 36,094 | 40,397 | 38,010 | -85,403 |
| Depreciation Amortization | 2,375 | 2,242 | 2,289 | 2,054 | 4,811 |
| Accounts receivable | 229 | -431 | 1,482 | -7,393 | 32,626 |
| Accounts payable and accrued liabilities | -4,240 | -4,049 | -3,066 | -2,983 | 687 |
| Other Working Capital | -104,735 | -102,761 | -94,884 | -82,113 | -30,959 |
| Other Operating Activity | 22,743 | 23,662 | 18,326 | 24,287 | 9,521 |
| Operating Cash Flow | $-50,940 | $-45,243 | $-35,456 | $-28,138 | $-68,717 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 17,200 | 9,315 | 11,780 | 17,199 | 8,870 |
| PPE Investments | 948 | 393 | 349 | N/A | -246 |
| Investing Cash Flow | $18,148 | $9,708 | $12,129 | $17,199 | $8,624 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -250 | -250 | -250 | -250 | -892 |
| Common Stock Issued | 16,349 | 16,352 | 1 | N/A | 60,181 |
| Other Financing Activity | -1 | -1 | 15,303 | 0 | -7 |
| Financing Cash Flow | $16,098 | $16,101 | $15,054 | $-250 | $59,282 |
| Beginning Cash Position | 25,176 | 25,176 | 25,176 | 25,176 | 25,987 |
| End Cash Position | 8,482 | 5,742 | 16,903 | 13,987 | 25,176 |
| Net Cash Flow | $-16,694 | $-19,434 | $-8,273 | $-11,189 | $-811 |
| Free Cash Flow | |||||
| Operating Cash Flow | -50,940 | -45,243 | -35,456 | -28,138 | -68,717 |
| Capital Expenditure | N/A | N/A | N/A | N/A | -246 |
| Free Cash Flow | -50,940 | -45,243 | -35,456 | -28,138 | -68,963 |